Sugi Predict

Sugi Predict / Compounds / SCHEMBL3409780

SCHEMBL3409780

SCHEMBL3409780

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@@H](CO)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.83
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ NR5A2 O00482 1/20 0.64
▸ NR5A1 Q13285 1/20 0.64
▸ S1PR1 P21453 1/20 0.64
▸ MAPT P10636 2/20 0.60
▸ FAAH O00519 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ CNR1 P21554 1/20 0.60
▸ CNR2 P34972 1/20 0.60
▸ RECQL P46063 1/20 0.60
▸ GPR55 Q9Y2T6 2/20 0.58
▸ ADRA1D P25100 1/20 0.53
▸ PTAFR P25105 1/20 0.53
▸ HTR1D P28221 1/20 0.53
▸ HTR2C P28335 1/20 0.53
▸ ADRA1B P35368 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ TMEM97 Q5BJF2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29440664 1.00 ALDH1A1 (0.83) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL4178822 0.98 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3410263 0.97 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL15689715 0.97 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3406019 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL753300 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3405833 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3403745 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3410573 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL5053766 0.94 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020102297-A1 Macromolecule-lipid complexes and methods for making and using THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-08-01 — — US claimed
WO-2000000033-A1 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-01-06 — — WO claimed
US-12263181-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS LLC (US) 2025-04-01 — — US disclosed
US-20220409641-A1 PHOSPHOLIPID COMPOSITIONS MACHAVERT PHARMACEUTICALS LLC (US) 2022-12-29 — — US disclosed
US-11433085-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS, LLC (US) 2022-09-06 — — US disclosed
US-20200046744-A1 Phospholipid Compositions MACHAVERT PHARMACEUTICALS, LLC 2020-02-13 — — US disclosed
US-10493086-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS LLC (US) 2019-12-03 — — US disclosed
US-20180028545-A1 PHOSPHOLIPID COMPOSITIONS MACHAVERT PHARMACEUTICALS, LLC 2018-02-01 — — US disclosed
US-20180000850-A1 PHOSPHOLIPID COMPOSITIONS MACHAVERT PHARMACEUTICALS LLC 2018-01-04 — — US disclosed
WO-2010126319-A2 LIPOPEPTIDE WITH SPECIFIC AFFINITY TO THE FC REGION OF AN ANTIBODY, AND ANTIGEN-RECOGNIZING LIPID NANOPARTICLE COMPRISING SAME 고려대학교 산학협력단 (KR) 2010-11-04 — — WO disclosed
EP-0958380-A4 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING UNIV CALIFORNIA (US) 2004-03-17 — — EP disclosed
EP-0958380-A1 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING The Regents of The University of California (US) 1999-11-24 — — EP disclosed
WO-1998035828-A9 LAMELLAR GELS AND METHODS FOR MAKING AND REGULATING — 1999-02-04 — — WO disclosed
WO-1998024936-A9 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING — 1998-10-01 — — WO disclosed
WO-1998035828-A1 LAMELLAR GELS AND METHODS FOR MAKING AND REGULATING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-08-20 — — WO disclosed
WO-1998024936-A1 MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-06-11 — — WO disclosed
EP-0161519-B1 DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-06-29 — — EP disclosed
US-4717512-A Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-01-05 — — US disclosed
US-4622180-A Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-11 — — US disclosed
EP-0161519-A2 Derivatives of glycerophosphocholine and of glycerophosphoethanol amine, their preparation and use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1985-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409641-A1 PHOSPHOLIPID COMPOSITIONS PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-10493086-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-11433085-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-20180028545-A1 PHOSPHOLIPID COMPOSITIONS PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-20200046744-A1 Phospholipid Compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-12263181-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-20180000850-A1 PHOSPHOLIPID COMPOSITIONS PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.